eQcell’s translational approach to development of its regenerative therapeutics bridges the initial veterinary concentration to the extension of the platform to human therapeutics. The veterinary therapy holds the prospect of rapid marketing approval and, in the process, generating data leading to a scientifically- and economically-effective pathway for continuing into similar human applications. That pathway reduces the significant risk and cost of late-stage failures in human drug development, and benefits the developer with early marketing revenues.
eQcell’s clinical status exhibits its leadership in the translational sciences at the industrial level, applying the principles of therapeutic development concurrently to both animal and human health.
eQcell is the beneficiary of partnerships with a range of acclaimed academic institutions and corporations worldwide.